Utilizing combinations of molecular targeted agents to sensitize tumor cells to EGFR inhibitors

摘要: EGFR inhibitors have achieved clinical antitumor activity as single agents. The specific inhibition of and associated pathways provides a mechanism for efficacious tumor cell growth while minimizing toxicities often with chemotherapeutic drugs. challenge using targeted cancer drugs agents is the potential de novo or acquired resistance due to established adapted alternate signal transduction pathways. In this chapter, we will describe how drug combinations can be rationally identified by utilizing our understanding molecular related biomarkers inhibitor sensitivity. Such may ultimately provide better efficacy reduced toxicity patients.